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Highlights 
 High throughput LC-MS/MS method to measure multiple vitamin D metabolites in serum. 
 SLE is an effective sample preparation method for multiple vitamin D metabolites. 
 Chiral column separation improves resolution between identical mass to charges. 
 Routine serum analysis shows correlations between active and inactive metabolites. 
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Abstract 
Recent studies suggest that vitamin D-deficiency is linked to increased risk of common human 
health problems. To define vitamin D ‘status’ most routine analytical methods quantify one 
particular vitamin D metabolite, 25-hydroxyvitamin D3 (25OHD3). However, vitamin D is 
characterized by complex metabolic pathways, and simultaneous measurement of multiple 
vitamin D metabolites may provide a more accurate interpretation of vitamin D status.  
To address this we developed a high-throughput liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) method to analyse multiple vitamin D analytes, with particular 
emphasis on the separation of epimer metabolites. A supportive liquid-liquid extraction (SLE) 
and LC-MS/MS method was developed to quantify 10 vitamin D metabolites as well as 
separation of an interfering 7α-hydroxy-4-cholesten-3-one (7αC4) isobar (precursor of bile acid), 
and validated by analysis of human serum samples.  
In a cohort of 116 healthy subjects, circulating concentrations of 25-hydroxyvitamin D3 
(25OHD3), 3-epi-25-hydroxyvitamin D3 (3-epi-25OHD3), 24,25-dihydroxyvitamin D3 
(24R,25(OH)2D3), 1,25-dihydroxyvitamin D3 (1α,25(OH)2D3), and 25-hydroxyvitamin D2 
(25OHD2) were quantifiable using 220 µl of serum, with 25OHD3 and 24R,25(OH)2D3 showing 
significant seasonal variations.  
This high-throughput LC-MS/MS method provides a novel strategy for assessing the impact of 
vitamin D on human health and disease. 
 
Keywords – LC-MS/MS, Vitamin D, Method validation, Chiral separation, Serum analysis. 
 
Word count: 188 
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1. Introduction 
In the last decade, studies of the prevalence of vitamin D deficiency and its clinical implications 
have increased demand for laboratory testing to determine vitamin D ‘status’ [1]. The most 
common approach to this has been the measurement of serum levels of 25-hydroxyvitamin D3 
(25OHD3). Compared to other vitamin D metabolites, 25OHD3 levels are significantly higher in 
serum and it has a relatively long serum half-life, making it an ideal marker for monitoring short 
and long-term changes in vitamin D status [1, 2]. Analytical methods detecting only 25OHD3 
metabolite can be automated, allowing laboratories with large sample demands to perform high 
throughput measurements of vitamin D [2]. 
 
Vitamin D occurs as two forms, D3 and D2, with approximately 95% of 25OHD circulating as 
the D3 form. Without dietary supplementation, only a small proportion of 25OHD is comprised 
of the D2 form [3, 4]. Contradictory data exists as to whether the D2 form, through 
supplementation, has less or equal effectiveness at maintaining vitamin D status and action in 
comparison to the D3 form [3]. The biologically active vitamin D metabolite, 1α,25(OH)2D, is 
formed by hydroxylation of 25OHD in the kidney [5]. The 1α,25(OH)2D3 metabolite is present 
in serum at low picomolar concentration ranges with a short half life time of 4 hours. These low 
concentration ranges have proved challenging for the development of analytical methods that can 
accurately measure this metabolite [6], particularly using less sensitive older generation LC-
MS/MS instruments. Chiral metabolites 23R,25(OH)2D3 and 24R,25(OH)2D3 can also be 
converted from 25OHD3, however unlike 1α,25(OH)2D3, these chiral metabolites are thought to 
be non-active [5]. 
 
Epimerisation of 25OHD2 and 25OHD3 form the C3-epimers, 3-epi-25OHD2 and 3-epi-
25OHD3 respectively [1]. The site of epimerisation occurs at the third carbon atom of 25OHD, 
altering the position of the hydroxyl group at this site. The structures of 25OHD and 3-epi-
25OHD are identical apart from the position of epimerisation [7]. 3-Epi-25OHD metabolites are 
hydroxylated to form 3-epi-1α,25(OH)2D, in the same manner of 25OHD is hydroxylated to form 
1α,25(OH)2D. The physiological role of 3-epi-1α,25(OH)2D remains unclear, although it is 
capable of binding to the vitamin D receptor with reduced physiological effect [8, 9]. 3-Epi-
1α,25(OH)2D does not raise calcium levels, whereas it has been shown to suppress parathyroid 
hormone in rats, as effectively as the 1α,25(OH)2D form [1, 8, 10, 11]. 
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Common techniques for quantifying vitamin D metabolites are immunoassays (IA), high 
performance liquid chromatography (HPLC) and liquid chromatography tandem-mass 
spectrometry (LC-MS/MS) [2, 12]. A comparison between IA and LC-MS/MS methods revealed 
variations in the accuracy between the two methods owing to matrix effects and binding 
specificity [6, 13]. Other limitations that have been observed for IA include variability between 
IA batches and deviation of analyte concentrations over a linear calibration range. Several IA 
methods are unable to distinguish between the two main forms of vitamin D (vitamin D3 and 
vitamin D2) and can be influenced by the variability in vitamin D binding protein, thereby 
reducing selectivity [6, 14-16]. Cross reactivity of 25OHD3 with 24,25(OH)2D3 occurs IA, this 
analyte can be present endogenously at low nanomolar concentration ranges [16]. LC-MS/MS 
has superior selectivity to IA, due to differentiation of analytes via chromatographic separation 
and differences in mass transitions.  
 
In a clinical setting LC-MS/MS is considered the most efficient reference method for measuring 
vitamin D ‘status’, being the most accurate analytical technique, particularly for quantification of 
multiple vitamin D analytes [6, 17]. Recent reports have highlighted the importance of accurate 
LC-MS/MS methods, and some scientific journals now only accept a fully validated assays for 
the analysis of steroids and sterols such as vitamin D [16, 18]. Sample preparation is required for 
LC-MS/MS analysis, to avoid matrix effects and concentrate sample if required, whereas in IA 
samples are analysed directly without any pre-processing meaning sample throughput is higher in 
IA which has an associated cost benefit [12]. 
 
Several techniques exist for preparing samples for LC-MS/MS analysis. A common approach is 
by liquid-liquid extraction (LLE) as this is considered a routine and inexpensive approach. 
However LLE can be time consuming, particularly for large sample batches as it can be difficult 
to automate. Supported liquid-liquid extraction (SLE) is a recently developed sample preparation 
technique that reduces sample preparation time compared to LLE. Both of these extraction 
techniques can be effective at removing matrix effects and avoiding extraction of any ionised 
compounds, particularly phospholipids that are associated with protein precipitation for vitamin 
D analysis [19]. As LLE is more time consuming, SLE is likely to be the preferred method of 
choice in the development of a high throughput assay for vitamin D LC-MS/MS analysis. The 
SLE method described here provides a more efficient protocol over LLE and protein 
precipitation methods, improving the extraction efficiency of protein precipitation and reducing 
sample preparation time over LLE without compromising analyte recovery. 
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Here we developed an LC-MS/MS assay capable of quantifying multiple vitamin D metabolites 
reflecting the principal vitamin D metabolic pathways. SLE for vitamin D was optimised as an 
alternative approach to other modes of sample extraction, and the optimised and validated 
methodology was applied to serum samples from healthy donors.  
 
2. Materials and methods 
2.1. Chemicals 
Reference standards for vitamin D metabolites (Table 1), formic acid, isopropanol, LC-MS 
grade ethyl acetate and methyl tert-butyl ether (MTBE) were purchased from Sigma Aldrich 
(Poole, UK). 7αC4 reference standard was purchased from LGC standards (Teddington, UK). A 
Lux cellulose-3 chiral column (100 mm, 2 mm, 3µm) and 96 well SLE plates were purchased 
from Phenomenex (Macclesfield, UK). A 2µm inline filter was purchased from Waters 
Corporation (Manchester, UK). Vitamin D depleted charcoal stripped serum was purchased from 
Golden West Biologicals Inc. (Temecula, US). LC-MS grade water was purchased from Fisher 
Scientific (Leicestershire, UK) and LC-MS grade methanol was purchased from Greyhound 
Chromatography (Merseyside, UK). External vitamin D calibrators and quality controls were 
purchased from Chromsystems (Am Haag, Germany). 
 
2.2. Preparation of standard solutions 
Vitamin D standards were purchased as stock solutions in ethanol. These were diluted in 
methanol to prepare standard curves ranging between 5-100 ng/mL and quality controls. All 
solutions were stored at -20 oC in amber salinized vials. Internal standards (1α,25(OH)2D3-d3, 
25OHD3-d3 and 3-epi-25OHD3-d3) were diluted to prepare a working solution, combining all 
the internal standards in methanol. 
 
2.3. Sample Collection 
116 healthy volunteers (79 women, 37 men) between 20 and 74 years of age and with a body 
mass index (BMI) between 20 and 30 kg/m2 were recruited from the local population 
(Birmingham, UK) (Z. H-S). Exclusion criteria included pregnancy and medical history of 
diabetes mellitus, ischemic heart disease, cerebrovascular disease, severe respiratory disease, and 
epilepsy. Patients arrived fasted at 8:30 am at the National Institute for Health Research (NIHR)-
Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital Birmingham. Venous 
blood was obtained via a peripheral cannula between 9 and 11am. 
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2.4. Ethical approval 
Ethical approval was obtained from the Coventry and Warwickshire Research Ethics Committee 
(REC reference no. 07/H1211/168) and NRES Committee West Midlands (REC reference no. for 
CHHIP 14/WM/1146). The protocol was approved by the Scientific Committee of the NIHR-
Wellcome Trust Clinical Research Facility at Queen Elizabeth Hospital Birmingham. The study 
visits were carried out between October 2010 and March 2013. Volunteers were given written 
and verbal information on the study, and written informed consent was obtained. After study 
completion, they received travel expenses, and clinically relevant results were passed on to 
general practitioners. 
 
2.5. Serum extraction 
Vitamin D analytes were extracted from 220 µL of serum. Firstly 20 µL of internal standard was 
added containing 3-epi-25OHD3-d3 (100 ng/mL), 25OHD3-d3 (100ng/mL) and 1α,25(OH)2D3-
d3 (50 ng/mL) in methanol/water (50/50%), the final internal standards in solution were 16,16 
and 8ng/mL respectively. Secondly proteins were precipitated using 80 µL of methanol, 50 µL 
isopropanol and 80 µL of water. The solution was then vortexed at high speed for 30 seconds and 
left for 7 minutes, followed by centrifugation at 7,516 x g for 5 minutes. Finally the supernatant 
was transferred onto the SLE plate, where the samples were completely absorbed into the SLE 
sorbent by applying a vacuum (5 Hg) for 10 seconds and left for 6 minutes. Vitamin D 
metabolites were extracted from the SLE wells by applying two 800 µL volumes of MTBE/ethyl 
acetate (90/10%), eluting under gravity initially, followed by applying a vacuum (5 Hg) to 
completely remove the final volume. The elution solvent was evaporated under nitrogen at 50 oC 
after each 800 µL addition. Samples were reconstituted in 125 µL water/methanol (50/50%) for 
LC-MS/MS analysis. 
 
 
2.6. LC-MS/MS analysis 
The LC-MS/MS system used was an ACQUITY ultra performance liquid chromatography 
(uPLC) coupled to a Waters Xevo TQ-S mass spectrometer (Waters, Manchester, UK). 
Ionisation was performed in electrospray ionisation (ESI) mode and the mass spectrometer was 
operated in positive ion mode. Multiple reaction monitoring (MRM) mode was used to monitor 
and quantify vitamin D analytes. The capillary voltage was 3.88 KV and the desolvation 
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temperature was 500 oC. The full mass spectrometry conditions (MRM transitions, cone voltage 
and collision energies) for each analyte are displayed in the Table 1. 
 
Chromatography separation was carried out using a Lux Cellulose-3 chiral column (100 mm, 2 
mm, 3 µm), which was maintained at 60 oC in a column oven. A 0.2 µm inline filter was added 
before the column to prevent blocking of the column and contamination. The mobile phase was 
methanol/water/0.1% formic acid at a flow rate of 330 µL/min. The mobile phase gradient is 
described is displayed in Supplementary Table 1. The total run time was 8 minutes per sample. 
 
2.7. Method validation 
Vitamin D depleted charcoal stripped serum, certified for vitamin D LC-MS/MS applications, 
was used as a negative control matrix. Known concentrations of vitamin D metabolites and 
internal standards were added to 220 µL charcoal stripped serum to prepare calibration and 
quality control (QC) standards, extracted using the same method as unknown samples. Method 
validation was carried out following US Food and Drug Administration (FDA) guidelines [20]. 
Method validation parameters assessed for this method were accuracy, precision, lower limit of 
quantification (LLOQ), lower limit of detection (LLOD), linearity, extraction recovery and 
selectivity. 
 
The accuracy and precision of the method was measured using replicates (N=6) at four 
concentration ranges to compare mean calculated values with nominal concentrations. Accuracy 
and precision was performed intra-day on the same day and inter-day with 6 replicates measured 
on three consecutive days. Accuracy was assessed by comparing QC concentrations to the 
nominal value. Precision was characterised by the relative standard deviation (RSD%) of the 
QC’s. Acceptable variation for accuracy and precision was set at 15%, and at 20% at the LLOQ. 
A calibration curve was produced for each compound by plotting known concentrations against 
the ratio of analyte peak area/internal standard. 
 
LLOD and LLOQ were determined by initially running known concentration standards of each 
metabolite, diluting concentrations and observing the peak signal with the corresponding signal 
to noise ratio (S/N). LLOD was the lowest concentration to produce a signal with S/N greater 
than 3:1. LLOQ was identified as the lowest concentration to produce a signal with S/N greater 
than 10:1 and was within FDA guidelines for accuracy and precision. Linearity of each 
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compound was monitored over a calibration range, analysed using Waters Target Lynx 
quantitative software. 
 
Extraction recoveries of each analyte was determined by comparing the peak area of extracted 
QC’s with the peak area of standard solutions at the same concentrations in water and methanol 
solution (50/50%). The method selectivity was observed by extracting an un-spiked charcoal 
stripped serum sample and confirming that no interfering signals were detected in the sample, 
particularly at the expected retention times of the vitamin D metabolites. Blank charcoal stripped 
serum was then extracted and spiked with water/methanol (50/50%) containing known vitamin D 
and internal standards concentrations. The concentrations were compared with standards at the 
same concentration in water and methanol solution (50/50%). 
 
2.8. Statistical analysis 
Statistical analysis was conducted using SPSS v22. The relationship between vitamin D 
metabolites was determined using Spearman one-tailed correlation coefficient. Group differences 
were tested using independent t-test and one-way ANOVA, the significance was set at P<0.05. 
The chromatography resolution factor was calculated as shown in Equation 1 [21]. 
𝑅𝑠 =
𝑡2− 𝑡1
1
2
 𝑊1+ 𝑊2
     (1) 
 
 
3. Results 
3.1. Method development 
The optimised mass spectrometry method detected and quantified 12 metabolites of vitamin D, 
four vitamin D deuterated internal standards, and the isobar 7αC4 in an unextracted standard 
solution prepared in water and methanol (50/50%). Following SLE extraction of charcoal 
stripped serum the vitamin D2 and D3 analogues and vitamin D2-d3 internal standard were 
retained on the SLE columns and could not be quantified. The final extraction and LC-MS/MS 
method was therefore capable of detecting 10 vitamin D metabolites, along with three internal 
standards and 7αC4. 
 
Further optimization was carried out to achieve maximum resolution of analytes, with the same 
MRM transitions; 25OHD3 and 3-epi-25OHD3, along with 1α,25(OH)2D3 and 24R,25(OH)2D3. 
Baseline chromatography separation of 25OHD3 and 25OHD2 with their respective 3-epi-
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25OHD compounds was achieved. The resolution factor between 25OHD and 3-epi-25OHD was 
3.81 and 4.71 for the D3 and D2 forms respectively. The achieved resolution was above the 
required 1.5 for accurate integration [21]. The method also achieved baseline separation of active 
1α,25(OH)2D3 with non-active chiral metabolites. Separation of 25OHD2 and 24OHD2 allowed 
quantification of these compounds separately, even though it was not possible to completely 
separate these metabolites at baseline. The resolution factor between 24OHD2 and 25OHD2 was 
0.76. A chromatogram of the vitamin D metabolites extracted from a spiked charcoal stripped 
serum is shown in Figure 1. Additional details of the method development are described in the 
Supplementary material. 
 
3.2. Method validation 
The inter-day and intra-day validation results for accuracy and precision were within the FDA 
guideline limits for each metabolite. Accuracy and precision results along with the LLOQ values 
are displayed in Table 2. The method showed good linearity for all compounds, the 
determination coefficient (R2) values were >0.98, apart from 3-epi-25OHD2 which had an R2 
value of 0.952. Extraction recovery and selectivity results are displayed in Supplementary 
material Table 2. Recovery values were between 63.05-90.44%, with variation in extraction 
efficiency between the D2 and D3 metabolites. The selectivity results to determine matrix effects 
confirmed that there were no interfering peaks from the matrix enhancing or suppressing the 
concentrations of any compounds. 
 
Cross validation with external Chromsystem calibrators and QC’s of 25OHD3 and 25OHD2 
were performed (Table 3). The calibration curves were within the accepted range for each 
calibration point, apart from the lowest 25OHD3 concentration. All QC points where within the 
Chromsystems acceptable concentration ranges. 
 
3.3. Application of method to donor serum analysis 
This method was applied to 116 serum samples from healthy humans (37 male, 79 female). 
Measurement of 25OHD3, 3-epi-25OHD3 and 24R,25(OH)2D3 was achieved in all samples. 
1α,25(OH)2D3 and 25OHD2 were quantifiable in 42 and 53 samples respectively (Table 4). A 
further 74 samples had detectable levels of 1α,25(OH)2D3 and 63 had detectable 25OHD2, 
however these levels were below the LLOQ. Seasonal variation in concentrations of the five 
vitamin D metabolites quantified in the human serum samples is shown in Figure 2. Data for 
serum analyses revealed correlation between concentrations of some vitamin D metabolites, 
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including 25OHD3 levels and 3-epi-25OHD3 (r = 0.687; p = <0.001), and 24R,25(OH)2D3 and 
25OHD3 (r= 0.916; p = <0.001) (Supplementary material Figure 2). The levels of 25OHD3 
and 1α,25(OH)2D3 (r = 0.212; p = 0.076) and 24R,25(OH)2D3 and 1α,25(OH)2D3 showed a 
significant linear correlation, which would be expected for a functional vitamin D pathway. 
Individual serum concentrations of vitamin D metabolites are displayed in Supplementary 
material Table 4.  
 
4. Conclusions 
In the current report we describe a novel optimised and validated high throughput (8 
mins/sample) LC-MS/MS method for analysis of multiple vitamin D metabolites. The 
endogenous reference ranges of 25OHD3, 3-epi25OHD3, 24R,25(OH)2D3 and 1α,25(OH)2D3 
from these samples correlated well with previous literature [22-25]. In the human serum 
validation studies 25OHD3 and 24R,25(OH)2D3 were quantified in all samples, with the cohort 
displaying a strong correlation of 25OHD3 with 24R,25(OH)2D3. Thus the method we describe 
here could be applied to assessment of the vitamin D pathway forming inactive 24R,25(OH)2D3 
catalysed by the enzyme 24-hydroxylase (CYP24A1) [24-26]. Mutations in CYP24A1, leading to 
inhibition oh 24-hydroxylase are associated with hypercalcemia and increased concentrations of 
the active vitamin D3 form [24, 27], whereas increased expression of CYP24A1 can lead to 
reduced levels of active vitamin D3 [28]. The application of this method could be used as an 
approach to identifying alterations in CYP24A1, where changes in correlation between 25OHD3 
and 24R,25(OH)2D3 are outside a control range. 
 
A key objective of this method was to assess the relative contribution of C3-epimer forms of 
vitamin D to the circulating concentrations of vitamin D metabolites. The MRM transitions of 
the C3-epimers are identical to their respective 25OHD isoforms, which could results in the 
interference of 25OHD3. Overestimation of 25OHD3 has occurred when 3-epi-25OHD3 has not 
been separated from 25OHD3 and the endogenous levels of 3-epi-25OHD3 are above the limits 
of quantification for the method [1, 29]. Levels of 3-epi-25OHD3 have been reported to be high 
in serum from new-borns and infants (<1 year old) [1, 6, 29, 30], but it is unclear whether this is 
enough to cause interference with 25OHD when the epimer is not chromatographically separated 
[8, 31]. Owing to the conflicting findings of 3-epi-25OHD3 levels, it was recommended that 3-
epi-25OHD3 should be separated when quantified along with 25OHD3 [32, 33]. The resolution 
we achieved for the separation of 3-epi-25OHD3 and 25OHD3 improved upon reported 
separations of these metabolites using a pentafluorophenyl (PFP) column [30, 32, 34]. This 
highlights the importance of separating these two metabolites. Finally, the new LC-MS/MS 
method further enhances the accuracy of 25OHD3 measurements by separating the endogenous 
isobar 7αC4 from both 25OHD3 and 3-epi-25OHD3. 
 
Levels of 24OHD2 were below the limits of detection in all samples measured. This metabolite 
did not interfere with 25OHD2 quantitation although baseline separation of 25OHD2 from 
24OHD2 could not be achieved. In data presented here, there was a trend towards higher levels 
of vitamin D analytes in samples where 25OHD2 was not quantifiable, with 3-epi-25OHD3 
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being significantly higher (p = 0.010). This effect of D2 could be particularly important when 
monitoring supplementation with this specific form of vitamin D. In the USA, vitamin D2 is the 
primary form of vitamin D used for higher dose therapy [3, 35], whereas both D2 and D3 are 
used in the UK and Europe [36]. Thus, analysis of multiple vitamin D metabolites as detailed in 
the current study would be important to identify metabolism after supplements are given and 
correlate any positive (or negative) health effects of these may be particularly important in 
patients where vitamin D2 is used as a supplement.  
 
The human cohort used to validate analysis of multiple vitamin D analytes was relatively vitamin 
D-deficient, based on current parameters defined by the Institute of Medicine in the USA [37], 
with mean serum 25OHD3 levels less than 40 nM (15.750 ± 8.704 ng/ml). Despite this it was 
possible to quantify low abundance analytes such as 1α,25(OH)2D3 and 25OHD2 in 
approximately 50% of the samples. It therefore seems likely that studies of more vitamin D-
replete cohorts will enable a broader range of analyte quantification. Although an application to 
serum samples is described here this method could also be useful for other settings including 
analysis of other biological fluids such as synovial fluid, where levels of some vitamin D 
metabolites such as 1α,25(OH)2D3 may be higher than in serum [38]. The functional importance 
of the other vitamin D metabolites included in the current analytical protocol is less clear at 
present, but these metabolites may become more relevant with changing trends in vitamin D 
research. Notably, the increasing interest in placebo-controlled supplementation trials using 
vitamin D3 or vitamin D2 means that it may be important to include analysis of less well 
characterised D2 metabolites such as 24OHD2, 1α,25(OH)2D2 and 3-epi-25OHD2 alongside 
more conventional D3 metabolites. Other vitamin D metabolites such as 23,25(OH)2D3 appear 
to play a central role in the catabolism of vitamin D [39] and may therefore provide systemic 
insight into the regulation of vitamin D metabolism and function. The new LC-MS/MS protocol 
may also be useful for cell culture experiments to elucidate vitamin D metabolism pathways for 
example 25OHD is frequently used as a substrate for analysis of localised, tissue-specific 
metabolism of 25OHD3 by cells such as macrophages [40].  
 
Acknowledgments 
Authors thank Theresa Brady, Pamela Jones, and Claire Brown (NIH Research-Wellcome Trust 
Clinical Research Facility), along with Dr JA Tamblyn and Dr R Susarla (Institute for 
Metabolism and Systems Research, The University of Birmingham). Professor Andrea Petroczi 
(Kingston University) is acknowledged for assistance with data analysis and statistical tests. 
Work was funded by an NIH P50 grant to MH and JSA (AR063020-01 NIH/NIAMS). Funding 
of the clinical visit was by European Research Council (Advanced Grant “Precort” to P.M.S.). 
 
Supplementary material 
Method development. 
Supplementary material Table 1. Liquid chromatography gradients. 
Supplementary material Table 2. Extraction recovery of each vitamin D metabolite at low, 
medium and high concentrations. 
Supplementary material Table 3. Selectivity concentrations comparing serum spiked 
concentrations post extraction and standard solution of each vitamin D metabolite. 
13 
 
Supplementary material Figure 1. Post column infusion of 25OHD3-d3 with chromatograms of 
A) blank charcoal stripped serum, B) 25OHD3-d3 spiked serum and C) LCMS grade water. 
Supplementary material Figure 2. Correlation between 25OHD3 and 3-epi-25OHD3 (R2 = 0.510) 
and 25OHD3 and 24R,25(OH)2D3 (R2 = 0.883). 
 
 
 
 
 
References 
 
[1] R.J. Singh, R.L. Taylor, G.S. Reddy, S.K.G. Grebe, C-3 epimers can account for a significant proportion of total 
circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D 
status, J Clin Endocr Metab, 91 (2006) 3055-3061. 
[2] C. Farrell, S. Martin, I. Straub, P. Williams, B. McWhinney, M. Herrmann, State of the Art of Vitamin D Assays: 
Latest Generation Assays, Osteoporosis Int, 22 (2011) S583-S583. 
[3] M.F. Holick, R.M. Biancuzzo, T.C. Chen, E.K. Klein, A. Young, D. Bibuld, R. Reitz, W. Salameh, A. Ameri, A.D. 
Tannenbaum, Vitamin D-2 is as effective as vitamin D-3 in maintaining circulating concentrations of 25-
hydroxyvitamin D, J Clin Endocr Metab, 93 (2008) 677-681. 
[4] H.M. Trang, D.E. Cole, L.A. Rubin, A. Pierratos, S. Siu, R. Vieth, Evidence that vitamin D3 increases serum 25-
hydroxyvitamin D more efficiently than does vitamin D2, The American journal of clinical nutrition, 68 (1998) 854-
858. 
[5] T. Higashi, K. Shimada, T. Toyo'oka, Advances in determination of vitamin D related compounds in biological 
samples using liquid chromatography-mass spectrometry: a review, Journal of chromatography. B, Analytical 
technologies in the biomedical and life sciences, 878 (2010) 1654-1661. 
[6] J.M. El-Khoury, E.Z. Reineks, S.H. Wang, Progress of liquid chromatography-mass spectrometry in measurement 
of vitamin D metabolites and analogues, Clinical biochemistry, 44 (2011) 66-76. 
[7] I. Shah, R. James, J. Barker, A. Petroczi, D.P. Naughton, Misleading measures in Vitamin D analysis: a novel LC-
MS/MS assay to account for epimers and isobars, Nutrition journal, 10 (2011) 46. 
[8] G. Lensmeyer, M. Poquette, D. Wiebe, N. Binkley, The C-3 Epimer of 25-Hydroxyvitamin D-3 Is Present in Adult 
Serum, J Clin Endocr Metab, 97 (2012) 163-168. 
[9] G.S. Reddy, K.R. Muralidharan, W.H. Okamura, K.Y. Tserng, J.A. Mclane, Metabolism of 1 alpha,25-
dihydroxyvitamin D-3 and one of its A-ring diastereomer 1 alpha,25-dihydroxy-3-epivitamin D-3 in neonatal human 
keratinocytes, Vitamin D, DOI (1994) 172-173. 
[10] S. Kadiyala, S. Nagaba, K. Takeuchi, S. Yukihiro, W. Qiu, S.T. Eyes, M.R. Uskokovic, G.H. Posner, G.S. Reddy, S.E. 
Guggino, Metabolites and analogs of 1alpha,25-dihydroxyvitamin D(3): evaluation of actions in bone, Steroids, 66 
(2001) 347-355. 
14 
 
[11] A.J. Brown, C.S. Ritter, A.S. Weiskopf, P. Vouros, G.J. Sasso, M.R. Uskokovic, G. Wang, G.S. Reddy, Isolation and 
identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion, Journal 
of cellular biochemistry, 96 (2005) 569-578. 
[12] A.M. Wallace, S. Gibson, A. de la Hunty, C. Lamberg-Allardt, M. Ashwell, Measurement of 25-hydroxyvitamin D 
in the clinical laboratory: current procedures, performance characteristics and limitations, Steroids, 75 (2010) 477-
488. 
[13] G.D. Carter, 25-Hydroxyvitamin D Assays: The Quest For Accuracy, Clinical chemistry, 55 (2009) 1300-1302. 
[14] H.J. Roth, H. Schmidt-Gayk, H. Weber, C. Niederau, Accuracy and clinical implications of seven 25-
hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference, 
Annals of clinical biochemistry, 45 (2008) 153-159. 
[15] B.W. Hollis, R.L. Horst, The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we 
are going, The Journal of steroid biochemistry and molecular biology, 103 (2007) 473-476. 
[16] A.E. Taylor, B. Keevil, I.T. Huhtaniemi, Mass spectrometry and immunoassay: how to measure steroid 
hormones today and tomorrow, European journal of endocrinology / European Federation of Endocrine Societies, 
173 (2015) D1-D12. 
[17] M. Vogeser, K.G. Parhofer, Liquid chromatography tandem-mass spectrometry (LC-MS/MS)--technique and 
applications in endocrinology, Experimental and clinical endocrinology & diabetes : official journal, German Society 
of Endocrinology [and] German Diabetes Association, 115 (2007) 559-570. 
[18] M.E. Wierman, R.J. Auchus, D.J. Haisenleder, J.E. Hall, D. Handelsman, S. Hankinson, W. Rosner, R.J. Singh, 
P.M. Sluss, F.Z. Stanczyk, Editorial: the new instructions to authors for the reporting of steroid hormone 
measurements, Endocrinology, 155 (2014) 4603. 
[19] B.G. Keevil, Novel liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for measuring 
steroids, Best practice & research. Clinical endocrinology & metabolism, 27 (2013) 663-674. 
[20] U.S.F.a.D. Administration, Guidance for Industry Bioanalytical Method Validation, 2001. 
[21] D. Song, J. Wang, Modified resolution factor for asymmetrical peaks in chromatographic separation, Journal of 
pharmaceutical and biomedical analysis, 32 (2003) 1105-1112. 
[22] L. Chailurkit, W. Aekplakorn, B. Ongphiphadhanakul, Serum C3 epimer of 25-hydroxyvitamin D and its 
determinants in adults: a national health examination survey in Thais, Osteoporosis international : a journal 
established as result of cooperation between the European Foundation for Osteoporosis and the National 
Osteoporosis Foundation of the USA, DOI 10.1007/s00198-015-3125-y(2015). 
[23] P.L. Lutsey, J.H. Eckfeldt, E.R. Ogagarue, A.R. Folsom, E.D. Michos, M. Gross, The 25-hydroxyvitamin D3 C-3 
epimer: distribution, correlates, and reclassification of 25-hydroxyvitamin D status in the population-based 
Atherosclerosis Risk in Communities Study (ARIC), Clinica chimica acta; international journal of clinical chemistry, 
442 (2015) 75-81. 
[24] D. Wagner, H.E. Hanwell, K. Schnabl, M. Yazdanpanah, S. Kimball, L. Fu, G. Sidhom, D. Rousseau, D.E. Cole, R. 
Vieth, The ratio of serum 24,25-dihydroxyvitamin D(3) to 25-hydroxyvitamin D(3) is predictive of 25-
hydroxyvitamin D(3) response to vitamin D(3) supplementation, The Journal of steroid biochemistry and molecular 
biology, 126 (2011) 72-77. 
15 
 
[25] M.J. Muller, D.A. Volmer, Mass Spectrometric Profiling of Vitamin D Metabolites beyond 25-Hydroxyvitamin D, 
Clinical chemistry, DOI 10.1373/clinchem.2015.241430(2015). 
[26] K.P. Schlingmann, M. Kaufmann, S. Weber, A. Irwin, C. Goos, U. John, J. Misselwitz, G. Klaus, E. Kuwertz-
Broking, H. Fehrenbach, A.M. Wingen, T. Guran, J.G. Hoenderop, R.J. Bindels, D.E. Prosser, G. Jones, M. Konrad, 
Mutations in CYP24A1 and idiopathic infantile hypercalcemia, The New England journal of medicine, 365 (2011) 
410-421. 
[27] J.R. Muindi, W.D. Yu, Y. Ma, K.L. Engler, R.X. Kong, D.L. Trump, C.S. Johnson, CYP24A1 inhibition enhances the 
antitumor activity of calcitriol, Endocrinology, 151 (2010) 4301-4312. 
[28] H.C. Horvath, P. Lakatos, J.P. Kosa, K. Bacsi, K. Borka, G. Bises, T. Nittke, P.A. Hershberger, G. Speer, E. Kallay, 
The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis, The journal of 
histochemistry and cytochemistry : official journal of the Histochemistry Society, 58 (2010) 277-285. 
[29] D. Bailey, K. Veljkovic, M. Yazdanpanah, K. Adeli, Analytical measurement and clinical relevance of vitamin D(3) 
C3-epimer, Clinical biochemistry, 46 (2013) 190-196. 
[30] J.M.W. van den Ouweland, A.M. Beijers, H. van Daal, Fast Separation of 25-Hydroxyvitamin D-3 from 3-Epi-25-
Hydroxyvitamin D-3 in Human Serum by Liquid Chromatography-Tandem Mass Spectrometry: Variable Prevalence 
of 3-Epi-25-Hydroxyvitamin D-3 in Infants, Children, and Adults, Clinical chemistry, 57 (2011) 1618-1619. 
[31] M.J.P. Wright, D.J. Halsall, B.G. Keevil, Removal of 3-Epi-25-Hydroxyvitamin D-3 Interference by Liquid 
Chromatography-Tandem Mass Spectrometry Is Not Required for the Measurement of 25-Hydroxyvitamin D-3 in 
Patients Older than 2 Years, Clinical chemistry, 58 (2012) 1719-1720. 
[32] M.W. Clarke, R.C. Tuckey, S. Gorman, B. Holt, P.H. Hart, Optimized 25-hydroxyvitamin D analysis using liquid-
liquid extraction with 2D separation with LC/MS/MS detection, provides superior precision compared to 
conventional assays, Metabolomics, 9 (2013) 1031-1040. 
[33] E.A. Yetley, C.M. Pfeiffer, R.L. Schleicher, K.W. Phinney, D.A. Lacher, S. Christakos, J.H. Eckfeldt, J.C. Fleet, G. 
Howard, A.N. Hoofnagle, S.L. Hui, G.L. Lensmeyer, J. Massaro, M. Peacock, B. Rosner, D. Wiebe, R.L. Bailey, P.M. 
Coates, A.C. Looker, C. Sempos, C.L. Johnson, M.F. Picciano, NHANES monitoring of serum 25-hydroxyvitamin D: a 
roundtable summary, The Journal of nutrition, 140 (2010) 2030S-2045S. 
[34] M. Yazdanpanah, D. Bailey, W. Walsh, B. Wan, K. Adeli, Analytical measurement of serum 25-OH-vitamin D(3), 
25-OH-vitamin D(2) and their C3-epimers by LC-MS/MS in infant and pediatric specimens, Clinical biochemistry, 46 
(2013) 1264-1271. 
[35] L.A.G. Armas, B.W. Hollis, R.P. Heaney, Vitamin D(2) is much less effective than vitamin D(3) in humans, J Clin 
Endocr Metab, 89 (2004) 5387-5391. 
[36] B.M.A.a.R.P.S.o.G. Britain, British National Formulary,  Vitamin D, 2015. 
[37] A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, 
R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes 
for calcium and vitamin D from the Institute of Medicine: what clinicians need to know, The Journal of clinical 
endocrinology and metabolism, 96 (2011) 53-58. 
[38] E.B. Mawer, M.E. Hayes, P.E. Still, M. Davies, G.A. Lumb, J. Palit, P.J. Holt, Evidence for nonrenal synthesis of 
1,25-dihydroxyvitamin D in patients with inflammatory arthritis, J Bone Miner Res, 6 (1991) 733-739. 
16 
 
[39] Y. Tanaka, H.F. DeLuca, H.K. Schnoes, N. Ikekawa, T. Eguchi, 23,25-Dihydroxyvitamin D3: a natural precursor in 
the biosynthesis of 25-hydroxyvitamin D3-26,23-lactone, Proceedings of the National Academy of Sciences of the 
United States of America, 78 (1981) 4805-4808. 
[40] M. Hewison, Vitamin D and the intracrinology of innate immunity, Molecular and cellular endocrinology, 321 
(2010) 103-111. 
  
17 
 
Legends to figures 
 
Figure 1. Chromatogram of vitamin D analytes extracted from a spiked serum quality 
control standard. All vitamin D metabolites could be quantified except vitamin D2, vitamin D 
and vitamin D2-d3 which could not be quantified from the SLE extraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1α,25(OH)2D3 
m/z – 399.3 
24R,25(OH)2D3 
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1α,25(OH)2D2 
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25OHD3 
m/z – 383.3 
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Vitamin D3 
m/z – 385.3 
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Figure 2. Seasonal variations in vitamin D metabolites. Circulating concentrations of 
25OHD3, 3-epi-25OHD3, 24R,25(OH)2D3, 1α,25(OH)2D3 and 25OHD2 in serum samples from 
116 healthy donors. Season was based on the date of sample collection broken down in the 
following date ranges; Winter-21/12-20/03; Spring-21/03-20/06; Summer-21/06-20/09; Autumn-
21/09-20/12. 
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Table 1. MRM transitions, collision energies and cone voltages of vitamin D metabolites. 
Compound Abbrev. MRM transitions 
Collision 
energy 
(eV) 
Cone 
voltage 
(V) 
25-hydroxyvitaminD3 25OHD3 
383.2   >   91.0 52 28 
383.2   >   107.0 32 28 
     
3-Epi-25-hydroxyvitaminD3 3-Epi25OHD3 
383.2   >   95.4 36 26 
383.2   >   107.0 32 26 
     
1α,25-dihydroxyvitaminD3 1α,25(OH)2D3 
399.2   >   105.1 46 22 
399.2   >   151.1 24 22 
     
23R,25-dihydroxyvitaminD3 23R,25(OH)2D3 
417.4   >   325.3 12 12 
417.4   >   343.3 10 12 
     
24R,25-dihydroxyvitaminD3 24R,25(OH)2D3 
417.4   >   121.1 14 14 
417.4   >   381.4 10 14 
     
25-hydroxyvitaminD2 25OHD2 
395.3   >   91.0 54 26 
395.3   >   119.0 22 26 
     
24-hydroxyvitaminD2 24OHD2 
395.3   >   340.9 36 66 
395.3   >   119.0 26 30 
     
3-Epi-25hydroxyvitaminD2 3-Epi-25OHD2 
395.3   >   91.0 50 26 
395.3   >   119.0 26 26 
     
1α,25- dihydroxyvitaminD2 1α,25(OH)2D2 
411.3   >   133.0 30 26 
411.3   >   151.0 22 26 
     
1α,24- dihydroxyvitaminD2 1α,24(OH)2D2 
411.3   >   133.0 30 26 
411.3   >   151.0 20 26 
     
Ergocalciferol Vitamin D2 
397.4   >   69.0 22 16 
397.4   >   107.1 28 16 
     
Cholecalciferol Vitamin D3 
385.4   >   107.0 30 20 
385.4   >   259.3 16 20 
     
7α-hydroxy-4-cholesten-3-one 7αC4 
401.4   >   97.0 26 34 
401.4   >   117.1 24 32 
     
1α,25-dihydroxyvitaminD3-d3 1α,25(OH)2D3-d3 
402.4   >   138.0 18 22 
402.4   >   154.1 20 22 
     
 
3-Epi-hydroxyvitamin-d3 3-Epi-25OHD3-d3 
404.4   >   107.2 40 40 
404.4   >   109.4 22 22 
404.4   >   368.4 12 12 
     
25-hydroxyvitaminD3 
 
25OHD3-d3 
 
386.4   >   95.1 26 26 
386.4   >   109.3 24 26 
    
 
Ergocalciferol-d3 
 
 
Vitamin D2-d3 
 
400.3   >   109.8 24 16 
400.3   >   69.02 30 16 
400.3   >   83.02 22 16 
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Table 2. Summary of accuracy and precision data for each vitamin D metabolite. 
Compound 
 
Concentration 
(ng/mL) 
 
Level 
    Precision (% RSD)  
Intra-day Inter-day Accuracy (%) 
25OHD3 
0.500 Low 7.61 9.20 100.15 
5.00 Medium 10.68 7.45 91.34 
20.00 High 4.18 4.93 106.84 
      
3-Epi-25OHD3 
0.188 Low 8.38 11.61 103.83 
1.875 Medium 8.41 6.10 111.74 
7.500 High 3.20 5.25 97.45 
      
1α,25(OH)2D3 
0.061 Low 9.64 8.20 111.80 
0.750 Medium 3.05 5.30 99.33 
2.000 High 4.29 4.20 99.96 
      
23R,25(OH)2D3 
1.00 Low 6.46 9.62 98.02 
4.00 Medium 9.31 9.17 98.56 
8.00 High 4.49 10.85 96.71 
      
24R,25(OH)2D3 
0.500 Low 6.19 8.13 98.62 
4.00 Medium 7.22 8.26 98.47 
8.00 High 6.08 8.48 100.40 
      
25OHD2 
1.000 Low 10.59 9.58 96.47 
2.500 Medium 9.52 8.38 92.91 
10.00 High 14.19 9.80 99.13 
      
24OHD2 
0.625 Low 9.26 7.07 99.11 
1.000 Medium 7.46 6.86 108.03 
2.500 High 3.37 5.65 90.77 
      
3-Epi-25OHD2 
0.500 Low 11.11 8.20 114.80 
1.875 Medium 3.75 6.62 110.89 
7.500 High 0.69 3.15 100.98 
      
1α,25(OH)2D2 
0.075 Low 10.44 7.88 90.44 
0.750 Medium 4.08 7.60 93.19 
2.000 High 5.34 3.63 102.87 
      
 0.0630 Low 8.45 10.91 96.30  
1α,25(OH)2D2 0.625 Medium 4.24 5.96 102.41  
 2.000 High 4.10 5.20 109.39  
       
 0.375 Low 5.54 8.00 106.13  
7αC4 3.750 Medium 9.81 8.71 96.07  
 15.00 High 7.85 8.20 98.5`5  
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Table 3. Chromsystems external calibrators. 
 
25OHD3    25OHD2   
Chromsystems 
concentration 
(ng/mL) 
Measured 
Concentration 
(ng/mL) 
 
%DEV 
 Chromsystems 
concentration 
(ng/mL) 
Measured 
Concentration 
(ng/mL) 
 
%DEV 
4.50 6.245 38.8  n.d 1.98  
9.70 8.967 -7.6  5.00 5.03 2.8 
18.50 19.176 3.7  14.30 14.69 2.7 
32.90 30.959 -5.9  28.60 27.75 -3.0 
65.60 67.321 2.6  57.10 65.56 14.8 
102.00 101.078 -0.9  98.60 106.90 8.4 
140.00 146.574 4.7  140.00 158.06 12.9 
QC (acceptable range 36.0-54.1 ng/mL)  QC (acceptable range 29.6-44.4 ng/mL) 
45.1 42.772   37.0 37.25  
45.1 48.372   37.0 40.99  
45.1 47.769   37.0 38.38  
45.1 44.178   37.0 33.37  
45.1 47.463   37.0 35.36  
 %CV = 4.8    %CV = 12.3  
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Table 4. Concentrations of serum vitamin D metabolites in serum 
 
Serum    
Compound  N = Mean ±SD (ng/mL) Range (ng/mL) 
25OHD3 116 15.750 ±8.704 2.166-42.706 
3-Epi-25OHD3 116 1.913 ±0.862 0.445-5.977 
24R,24(OH)2D3 116 2.499 ±2.184 0.084-9.514 
25OHD2 53 1.795 ±2.979 0.157-15.921 
Compound  N = Mean ±SD (pg/mL) Range (pg/mL) 
1α,25(OH)2D3  42      47.957 ±12.855 32.514-85.389 
 
 
 
